5
项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的临床试验A Single-center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With SUBLIVAC FIX Phleum Pratense in Grass Pollen-Allergic Subjects With IgE-Mediated Seasonal ARC
The purpose of this study is to assess safety, tolerability and demonstrate a dose response signal using Total Symptom Score (TSS), based on challenges with grass pollen in an Environmental Exposure Chamber (EEC), followed by estimation of the minimum effective dose of SUBLIVAC FIX Phleum (SP) after 10 months of treatment compared to placebo.
The study has 4 treatment groups: 3 different doses of SP and placebo will be tested.
A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Phleum pratense in patients with allergic rhinitis/rhinoconjunctivitis caused by grass pollen - SUBLIVAC FIX Phleum pratense DT/DRF
A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Phleum Pratense in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Grass Pollen
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Phleum pratense based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Phleum pratense compared to placebo. Furthermore, safety and tolerability will be assessed by the number of related Adverse Events of different dosages of SUBLIVAC FIX Phleum pratense compared to placebo.
100 项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的临床结果
100 项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的转化医学
100 项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的专利（医药）
100 项与 Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) 相关的药物交易
